Literature DB >> 15996942

An enzyme-linked immunosorbent assay to screen for inhibitors of the oncogenic anaplastic lymphoma kinase.

Rosalind Helen Gunby, Carmen Julia Tartari, Francesca Porchia, Arianna Donella-Deana, Leonardo Scapozza, Carlo Gambacorti-Passerini.   

Abstract

The discovery of novel anti-cancer drugs targeting anaplastic lymphoma kinase (ALK), an oncogenic tyrosine kinase, raises the need for in vitro assays suitable for screening compounds for ALK inhibition. To this aim we have developed and optimized an ALK-specific enzyme-linked immunosorbent assay that employs a novel ALK peptide substrate and purified ALK kinase domain.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15996942

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  6 in total

1.  Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation.

Authors:  Addolorata Maria Luce Coluccia; Angelo Vacca; Mireia Duñach; Luca Mologni; Sara Redaelli; Victor H Bustos; Daniela Benati; Lorenzo A Pinna; Carlo Gambacorti-Passerini
Journal:  EMBO J       Date:  2007-02-22       Impact factor: 11.598

2.  NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma.

Authors:  Annamaria Galietta; Rosalind H Gunby; Sara Redaelli; Paola Stano; Cristiana Carniti; Angela Bachi; Philip W Tucker; Carmen J Tartari; Ching-Jung Huang; Emanuela Colombo; Karen Pulford; Miriam Puttini; Rocco G Piazza; Holger Ruchatz; Antonello Villa; Arianna Donella-Deana; Oriano Marin; Danilo Perrotti; Carlo Gambacorti-Passerini
Journal:  Blood       Date:  2007-05-30       Impact factor: 22.113

3.  Dissection of the RET/β-catenin interaction in the TPC1 thyroid cancer cell line.

Authors:  Carmen J Tartari; Carla Donadoni; Elisa Manieri; Luca Mologni; Pamela Della Mina; Antonello Villa; Carlo Gambacorti-Passerini
Journal:  Am J Cancer Res       Date:  2011-06-01       Impact factor: 6.166

Review 4.  ALK and ROS1 as a joint target for the treatment of lung cancer: a review.

Authors:  Raimon Puig de la Bellacasa; Niki Karachaliou; Roger Estrada-Tejedor; Jordi Teixidó; Carlota Costa; José I Borrell
Journal:  Transl Lung Cancer Res       Date:  2013-04

Review 5.  Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.

Authors:  Thomas R Webb; Jake Slavish; Rani E George; A Thomas Look; Liquan Xue; Qin Jiang; Xiaoli Cui; Walter B Rentrop; Stephan W Morris
Journal:  Expert Rev Anticancer Ther       Date:  2009-03       Impact factor: 4.512

Review 6.  Anaplastic lymphoma kinase: signalling in development and disease.

Authors:  Ruth H Palmer; Emma Vernersson; Caroline Grabbe; Bengt Hallberg
Journal:  Biochem J       Date:  2009-05-27       Impact factor: 3.857

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.